Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-Blinded, Phase 3 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

NCT05463068 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT05463068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05463068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-Blinded, Phase 3 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
Lead sponsor
Novavax
Phase
Phase 3
Overall status
Completed
Start date
July 11, 2022
Completion date
September 1, 2022
Enrollment
911 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection